Cellromax Science Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	3,418	2,966	3,817
Depreciation & Amortization	476.9	478.45	435.41
Loss (Gain) From Sale of Assets	-10.82	-10.82	-11.85
Loss (Gain) From Sale of Investments	-117.13	-127.93	-71.81
Stock-Based Compensation	218.44	336.48	-
Provision & Write-off of Bad Debts	-	-	8.37
Other Operating Activities	532.62	159.73	2,523
Change in Accounts Receivable	-285.63	55.65	-26.06
Change in Inventory	-1,302	-969.11	-589.25
Change in Accounts Payable	-77.06	66.38	291.89
Change in Other Net Operating Assets	-723.51	-1,170	-82.77
Operating Cash Flow	2,130	1,785	6,294
Operating Cash Flow Growth	-57.50%	-71.64%	-
Capital Expenditures	-77.96	-78.64	-206.22
Sale of Property, Plant & Equipment	6.64	6.64	13.45
Sale (Purchase) of Intangibles	569.25	533.9	-2,547
Investment in Securities	2,360	1,437	-13,537
Other Investing Activities	2,186	2,122	-163.8
Investing Cash Flow	5,044	4,020	-16,441
Long-Term Debt Repaid	-	-265.24	-179.49
Net Debt Issued (Repaid)	-268.31	-265.24	-179.49
Repurchase of Common Stock	-1,509	-2,527	-17.27
Dividends Paid	-3,389	-3,389	-
Other Financing Activities	-0	-0	9,477
Financing Cash Flow	-5,166	-6,181	9,280
Foreign Exchange Rate Adjustments	-0.41	-0.41	0.55
Miscellaneous Cash Flow Adjustments	-0	-	0
Net Cash Flow	2,007	-376.11	-865.86
Free Cash Flow	2,052	1,707	6,088
Free Cash Flow Growth	-57.55%	-71.97%	-
Free Cash Flow Margin	9.78%	7.69%	28.15%
Free Cash Flow Per Share	180.64	149.58	585.32
Cash Interest Paid	28.25	28.49	30.35
Cash Income Tax Paid	58.15	1,131	918.62
Levered Free Cash Flow	-152.3	1,702	-
Unlevered Free Cash Flow	-128.42	1,733	-
Change in Working Capital	-2,389	-2,017	-406.19